EZH2 and neoplasm: In a mouse xenograft model, tumours were almost entirely eliminated following twice-daily 250 mg kg−1 dosing, with no re-growth observed 32 days post-dose.205 In an EZH2-mutant lymphoma models, tazemetostat potently induced a reduction in H3K27me3 marks (IC50 = 9 nM),206 and in mouse xenografts, dose-dependent growth inhibition was observed along with complete and sustained tumour regression after 28 days.